Research Library / Metabolic / CagriSema
Metabolic researchCagriSema
Cagrilintide + semaglutide
An investigational once-weekly combination of cagrilintide and semaglutide. The listed community example (community combination reports) describes Components titrated separately per administration, once weekly, via subcutaneous; this is not a validated dosing recommendation. No standardized generic reconstitution example is established. For research and education only, not personal medical guidance.
Quick Reference
- Evidence
- Phase III
- Presentation
- Not standardized
- Clinical context
- See cited product or study
- Diluent
- Not assigned
This investigational fixed-ratio combination is product- and trial-specific; separate component vial math would not reproduce the studied formulation.
Research schedules
| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| REDEFINE phase 3 target-dose reference | 2.4 mg cagrilintide + 2.4 mg semaglutide | 4.8 mg total/week | Once weekly with flexible dose adjustment | Same day each week | Subcutaneous | Trial-derived reference |
Cagrilintide 2.4 mg + semaglutide 2.4 mg target doses · subcutaneous · once weekly · 68 weeks · flexible dose adjustment
3,417 adults with obesity or overweight plus a comorbidity, without type 2 diabetesNEJM, 2025Cagrilintide 2.4 mg + semaglutide 2.4 mg target doses · subcutaneous · once weekly · 68 weeks · flexible dose adjustment
1,206 adults with obesity or overweight and type 2 diabetesNEJM, 2025| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| Community combination reports | Components titrated separately | Variable weekly total | Once weekly | Same day each week | Subcutaneous | Community-reported |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
No standardized example
This investigational fixed-ratio combination is product- and trial-specific; separate component vial math would not reproduce the studied formulation.
Supplies & vial yield
Supply total not calculated
No standardized injectable planning basis
This investigational fixed-ratio combination is product- and trial-specific; separate component vial math would not reproduce the studied formulation.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- CagriSema · Cagrilintide + semaglutide
- Evidence / status
- Phase III. Investigational — FDA application submitted; not approved
- Clinical route, frequency & duration
REDEFINE 1 phase 3 trial: Cagrilintide 2.4 mg + semaglutide 2.4 mg target doses · subcutaneous · once weekly · 68 weeks · flexible dose adjustment
REDEFINE 2 phase 3 trial: Cagrilintide 2.4 mg + semaglutide 2.4 mg target doses · subcutaneous · once weekly · 68 weeks · flexible dose adjustment
- Community purpose
- Weight management and appetite control through combined GLP-1 and amylin pathways.
Loading, titration and maintenance
A separate loading phase is not identified in this library entry. Titration, maintenance and stopping rules depend on the specific product or study; a listed range is not automatically an escalation plan.
Reconstitution & formulation
Patents describe both separated formulations and engineered coformulations, including investigations of pH-dependent fibrillation. The ability to formulate a combination does not validate an arbitrary same-vial powder.
Other vehicles and approaches discussed
Individual semaglutide and cagrilintide solvent instructions cannot establish finished-blend compatibility. No universal BAC/PBS/acid recipe is given here.
- Evidence context
- Product / laboratory / report distinctions apply
- Cloudiness / gel signal
- Finished-blend compatibility and aggregation concern
- Product details to verify
- Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.
Sources apply to the named product, laboratory method or report only. Laboratory solvents and community repetition do not establish an injectable preparation, sterility, chemical stability or a beyond-use period. No solvent-mixing or salvage recipe is provided.
Preparation references reviewed October 20, 2026.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Finished-blend compatibility and aggregation concern
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Combined amylin and GLP-1 receptor agonism
An investigational once-weekly combination of cagrilintide and semaglutide. Phase 3 results are published, but the combination remains unapproved while its U.S. application is under review.
Community-reported purpose
Weight management and appetite control through combined GLP-1 and amylin pathways.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
REDEFINE 1 phase 3 trial
Protocol: Cagrilintide 2.4 mg + semaglutide 2.4 mg target doses · subcutaneous · once weekly · 68 weeks · flexible dose adjustment
Population: 3,417 adults with obesity or overweight plus a comorbidity, without type 2 diabetes
Read the cited evidenceREDEFINE 2 phase 3 trial
Protocol: Cagrilintide 2.4 mg + semaglutide 2.4 mg target doses · subcutaneous · once weekly · 68 weeks · flexible dose adjustment
Population: 1,206 adults with obesity or overweight and type 2 diabetes
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
Gastrointestinal adverse events were common in phase 3. Flexible dosing means the target dose should not be presented as a universal starting dose or self-directed schedule.
Development and regulatory status
Investigational — FDA application submitted; not approved
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is CagriSema?
An investigational once-weekly combination of cagrilintide and semaglutide. Phase 3 results are published, but the combination remains unapproved while its U.S. application is under review.
Combined amylin and GLP-1 receptor agonism
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
A separate loading phase is not identified in this entry. Do not infer one from a range of reported amounts.
Cycle length is not established as a universal protocol.
Which diluent and storage period should this material use?
Patents describe both separated formulations and engineered coformulations, including investigations of pH-dependent fibrillation. The ability to formulate a combination does not validate an arbitrary same-vial powder.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapeNEJM, 2025: REDEFINE 1 phase 3 trial
- Clinical / regulatory / evidence landscapeNEJM, 2025: REDEFINE 2 phase 3 trial
- Formulation-development patent — not a clinical protocolNovo Nordisk formulation patent WO2024256632A1
- Formulation-development patent — not a clinical protocolNovo Nordisk dual-chamber formulation patent
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.